Estrogen and colorectal cancer incidence and mortality

Cancer

Volumn 121, Issue 18, 2015, Pages 3261-3271

  Lavasani, Sayeh ^a,b   Chlebowski, Rowan T ^c   Prentice, Ross L ^d   Kato, Ikuko ^a,b   Wactawski Wende, Jean ^e   Johnson, Karen C ^f   Young, Alicia ^d   Rodabough, Rebecca ^d   Hubbell, F Allan ^g   Mahinbakht, Ali ^h   Simon, Michael S ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c HARBOR UCLA MEDICAL CENTER   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e UNIVERSITY AT BUFFALO   (United States)

^f UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

colorectal cancer; estrogen; incidence; mortality; postmenopausal women

Indexed keywords

CONJUGATED ESTROGEN; PLACEBO; ESTROGEN;

ADULT; AGED; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER STAGING; COLON CANCER; COLON POLYP; COLORECTAL CANCER; CONFERENCE PAPER; FEMALE; HUMAN; MULTICENTER STUDY (TOPIC); PATIENT HISTORY OF HYSTERECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; ADENOCARCINOMA; COLORECTAL NEOPLASMS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; ESTROGEN THERAPY; FOLLOW UP; INCIDENCE; MIDDLE AGED; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ADENOCARCINOMA; AGED; COLORECTAL NEOPLASMS; DOUBLE-BLIND METHOD; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; ESTROGENS, CONJUGATED (USP); FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MIDDLE AGED;

EID: 84940940030     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29464     Document Type: Conference Paper

References (34)

1. Grodstein F, Newcomb PA, Stampfer MJ,. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med. 1999; 106: 574-582.
2. Nanda K, Bastian LA, Hasselblad V, Simel DL,. Hormone replacement therapy and the risk of colorectal cancer: a meta-analysis. Obstet Gynecol. 1999; 93 (5 pt 2): 880-888.
3. Foster PA,. Oestrogen and colorectal cancer: mechanisms and controversies. Int J Colorectal Dis. 2013; 28: 737-749.
4. Lin KJ, Cheung WY, Lai JY, Giovannucci EL,. The effect of estrogen vs. combined estrogen-progestogen therapy on the risk of colorectal cancer. Int J Cancer. 2012; 130: 419-430.
5. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, et al., Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med. 2004; 350: 991-1004.
6. Simon MS, Chlebowski RT, Wactawski-Wende J, et al., Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol. 2012; 30: 3983-3990.
7. Ritenbaugh C, Stanford JL, Wu L, et al., Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev. 2008; 17: 2609-2618.
8. Manson JE, Chlebowski RT, Stefanick ML, et al., Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013; 310: 1353-1368.
9. Hays J, Hunt JR, Hubbell FA, et al., The Women's Health Initiative recruitment methods and results. Ann Epidemiol. 2003; 13 (9 suppl): S18-S77.
10. Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials. 1998; 19: 61-109.
11. Anderson GL, Manson J, Wallace R, et al., Implementation of the Women's Health Initiative study design. Ann Epidemiol. 2003; 13 (9 suppl): S5-S17.
12. Curb JD, McTiernan A, Heckbert SR, et al., Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol. 2003; 13 (9 suppl): S122-S128.
13. National Cancer Institute. About the SEER program. http://seer.cancer.gov/about/. Accessed May 4, 2015.
14. Anderson GL, Limacher M, Assaf AR, et al., Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004; 291: 1701-1712.
15. LaCroix AZ, Chlebowski RT, Manson JE, et al., Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA. 2011; 305: 1305-1314.
16. Prentice RL, Pettinger M, Beresford SA, et al., Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1531-1537.
17. Johnson JR, Lacey JV Jr, Lazovich D, et al., Menopausal hormone therapy and risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18: 196-203.
18. Delellis Henderson K, Duan L, Sullivan-Halley J, et al., Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers Study. Am J Epidemiol. 2010; 171: 415-425.
19. Hildebrand JS, Jacobs EJ, Campbell PT, et al., Colorectal cancer incidence and postmenopausal hormone use by type, recency, and duration in cancer prevention study II. Cancer Epidemiol Biomarkers Prev. 2009; 18: 2835-2841.
20. Risch HA, Howe GR,. Menopausal hormone use and colorectal cancer in Saskatchewan: a record linkage cohort study. Cancer Epidemiol Biomarkers Prev. 1995; 4: 21-28.
21. Tannen RL, Weiner MG, Xie D, Barnhart K,. Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod. 2007; 22: 1769-1777.
22. Newcomb PA, Storer BE,. Postmenopausal hormone use and risk of large-bowel cancer. J Natl Cancer Inst. 1995; 87: 1067-1071.
23. Campbell PT, Newcomb P, Gallinger S, Cotterchio M, McLaughlin JR,. Exogenous hormones and colorectal cancer risk in Canada: associations stratified by clinically defined familial risk of cancer. Cancer Causes Control. 2007; 18: 723-733.
24. Wu AH, Siegmund KD, Long TI, et al., Hormone therapy, DNA methylation and colon cancer. Carcinogenesis. 2010; 31: 1060-1067.
25. Csizmadi I, Collet JP, Benedetti A, Boivin JF, Hanley JA,. Defining hormone replacement therapy in longitudinal studies: impact on measures of effect. Pharmacoepidemiol Drug Saf. 2004; 13: 215-225.
26. Hoffmeister M, Raum E, Krtschil A, Chang-Claude J, Brenner H,. No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy. Clin Pharmacol Ther. 2009; 86: 416-424.
27. Barzi A, Lenz AM, Labonte MJ, Lenz HJ,. Molecular pathways: estrogen pathway in colorectal cancer. Clin Cancer Res. 2013; 19: 5842-5848.
28. Morois S, Fournier A, Clavel-Chapelon F, Mesrine S, Boutron-Ruault MC,. Menopausal hormone therapy and risks of colorectal adenomas and cancers in the French E3N prospective cohort: true associations or bias? Eur J Epidemiol. 2012; 27: 439-452.
29. Majek O, Gondos A, Jansen L, et al,; GEKID Cancer Survival Working Group. Sex differences in colorectal cancer survival: population-based analysis of 164,996 colorectal cancer patients in Germany. PLoS One. 2013; 8: e68077.
30. Persson I, Yuen J, Bergkvist L, Schairer C,. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy-long-term follow-up of a Swedish cohort. Int J Cancer. 1996; 67: 327-332.
31. Tsilidis KK, Allen NE, Key TJ, et al., Menopausal hormone therapy and risk of colorectal cancer in the European Prospective Investigation Into Cancer and Nutrition. Int J Cancer. 2011; 128: 1881-1889.
32. Mandelson MT, Miglioretti D, Newcomb PA, Harrison R, Potter JD,. Hormone replacement therapy in relation to survival in women diagnosed with colon cancer. Cancer Causes Control. 2003; 14: 979-984.
33. Slattery ML, Anderson K, Samowitz W, et al., Hormone replacement therapy and improved survival among postmenopausal women diagnosed with colon cancer (USA). Cancer Causes Control. 1999; 10: 467-473.
34. Siegel R, Desantis C, Jemal A,. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014; 64: 104-117.